VJHemOnc Podcast

Experts discuss key updates in multiple myeloma treatments from ASH 2020, including the debate on autologous transplantation, benefits of early transplant, CAR T-cell therapy results, efficacy and side effects of different drugs, and the impact of CAR-T and T-cell engagers on quality of life.

Experts in this podcast discuss the latest advancements in genomic discoveries and treatment strategies for myeloproliferative neoplasms (MPNs). They explore clonal evolution discoveries, the burden of polycythemia vera (PV), and the pipeline for myelofibrosis (MF) treatments. Additionally, they highlight the exciting advancements in targeted therapies for rare blood cancers and the potential for new drugs in 2021.

Leading experts in MDS management discuss key updates from ASH 2020. Topics include Phase II IMerge trial results for imetelstat, Phase Ib study on venetoclax and azacitidine combination, and Phase I trial investigating decitabine with ipilimumab for relapsed/refractory MDS or AML.

Highlights from the ASH 2020 conference on AML include updates on Venetoclax as a major drug, challenges and benefits of AML treatments, the effectiveness of Flip 3 inhibitors in heavily pretreated patients, limitations of response assessments, and promising early data on oral Mening inhibitors for AML therapy.

Experts from various countries discuss the challenges, diagnosis, and treatment of MDS worldwide, including the variations in epidemiological data. They explore difficulties in diagnosis and treatment, such as limited resources and access to genetic testing. The speakers also address challenges in accessing standard treatments, the cost of transplantation in Mexico and Brazil, and difficulties in treating MDS in India. Additionally, they discuss the affordability of drugs, stem cell transplantation, and innovative approaches for improving the quality of life for MDS patients.

Discussion on prognostic factors in light chain amyloidosis, including the link between measurable monoclonal spike and survival outcomes. Review of the safety, efficacy, and pharmacokinetics of Kyle 101 monoclonal antibody therapy. Analysis of treatment trends in amyloidosis, highlighting improvements in hematologic response rates and overall survival for stage 2 and 3A disease.

In this podcast, Nitin Jain, MD, and Anthony Mato, MD, discuss the latest updates in CLL treatment at ASH 2020, including MRD outcomes, Bruin trial results, and retreatment with Venetoclax. The Bruin trial of Loxo305 showed promising results in mantle cell lymphoma, and a retrospective study revealed a high overall response rate with retreatment using Venetoclax.

Experts discuss novel immunotherapies, CARTITUDE-1 study results, and developments in multiple myeloma therapy with a focus on BCMA targeted therapy using CAR-T cells.

Updates from ASH 2020 on CAR T-cell therapy for lymphoma, including promising results in relapsed/refractory follicular lymphoma. Safety and efficacy of Liza Cell in relapsed/refractory mantle cell lymphoma. Comparison between different CAR T-cell therapies and introduction of Auto3 with dual targeting. Clinical trial testing dual targeting CAR with Pembroluzemab for lymphoma, including patient updates and long-term persistence.

Jyoti Nangalia and Srdan Verstovsek discuss MPN pathogenesis and novel therapies from ASH 2020. Topics covered include early acquisition of JAC2 mutation, CPI-610 study for myelofibrosis treatment, and efficacy of Avaprytineib in indolent systemic mastocytosis.